These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
268 related articles for article (PubMed ID: 36316100)
1. Outcomes and drivers of inappropriate dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a systematic review and meta-analysis. Caso V; de Groot JR; Sanmartin Fernandez M; Segura T; Blomström-Lundqvist C; Hargroves D; Antoniou S; Williams H; Worsley A; Harris J; Caleyachetty A; Vardar B; Field P; Ruff CT Heart; 2023 Jan; 109(3):178-185. PubMed ID: 36316100 [TBL] [Abstract][Full Text] [Related]
2. Off-label dosing of non-vitamin K antagonist oral anticoagulants and clinical outcomes in Asian patients with atrial fibrillation. Chan YH; Chao TF; Chen SW; Lee HF; Yeh YH; Huang YC; Chang SH; Kuo CT; Lip GYH; Chen SA Heart Rhythm; 2020 Dec; 17(12):2102-2110. PubMed ID: 32702416 [TBL] [Abstract][Full Text] [Related]
3. Label Adherence of Direct Oral Anticoagulants Dosing and Clinical Outcomes in Patients With Atrial Fibrillation. Yu HT; Yang PS; Jang E; Kim TH; Uhm JS; Kim JY; Pak HN; Lee MH; Lip GYH; Joung B J Am Heart Assoc; 2020 Jun; 9(12):e014177. PubMed ID: 32495677 [TBL] [Abstract][Full Text] [Related]
4. Clinical consequences of off-label reduced dosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis. Joosten LPT; van Maanen R; van den Dries CJ; Rutten FH; Hoes AW; Granger CB; Hemels MEW; Geersing GJ; van Doorn S Open Heart; 2023 May; 10(1):. PubMed ID: 37169490 [TBL] [Abstract][Full Text] [Related]
5. Pattern and Impact of Off-label Underdosing of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Who are Indicated for Standard Dosing. Cho MS; Yun JE; Park JJ; Kim YJ; Lee J; Kim H; Park DW; Nam GB Am J Cardiol; 2020 May; 125(9):1332-1338. PubMed ID: 32098658 [TBL] [Abstract][Full Text] [Related]
6. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses. Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628 [TBL] [Abstract][Full Text] [Related]
7. Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry. Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Kowey PR; Mahaffey KW; Naccarelli G; Reiffel J; Singer DE; Peterson ED; Piccini JP; J Am Coll Cardiol; 2016 Dec; 68(24):2597-2604. PubMed ID: 27978942 [TBL] [Abstract][Full Text] [Related]
8. Comparisons of effectiveness and safety between on-label dosing, off-label underdosing, and off-label overdosing in Asian and non-Asian atrial fibrillation patients treated with rivaroxaban: a systematic review and meta-analysis of observational studies. Chan YH; Chan CY; Chen SW; Chao TF; Lip GYH Europace; 2023 Oct; 25(10):. PubMed ID: 37738425 [TBL] [Abstract][Full Text] [Related]
9. Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events With Warfarin Use vs Non-vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation With a History of Intracranial Hemorrhage. Tsai CT; Liao JN; Chiang CE; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Chung FP; Chao TF; Lip GYH; Chen SA JAMA Netw Open; 2020 Jun; 3(6):e206424. PubMed ID: 32478848 [TBL] [Abstract][Full Text] [Related]
10. Off-label underdosing of four individual NOACs in patients with nonvalvular atrial fibrillation: A systematic review and meta-analysis of observational studies. Sang C; Chen J; Sun J; Lai Y; Liu X; Zhu W Eur J Clin Invest; 2022 Oct; 52(10):e13819. PubMed ID: 35643840 [TBL] [Abstract][Full Text] [Related]
11. Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) Versus Warfarin in Patients with Atrial Fibrillation and (Morbid) Obesity or Low Body Weight: a Systematic Review and Meta-Analysis. Grymonprez M; De Backer TL; Steurbaut S; Boussery K; Lahousse L Cardiovasc Drugs Ther; 2022 Aug; 36(4):749-761. PubMed ID: 33428092 [TBL] [Abstract][Full Text] [Related]
12. Frequency and Outcomes of Reduced Dose Non-Vitamin K Antagonist Anticoagulants: Results From ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II). Steinberg BA; Shrader P; Pieper K; Thomas L; Allen LA; Ansell J; Chan PS; Ezekowitz MD; Fonarow GC; Freeman JV; Gersh BJ; Kowey PR; Mahaffey KW; Naccarelli GV; Reiffel JA; Singer DE; Peterson ED; Piccini JP; J Am Heart Assoc; 2018 Feb; 7(4):. PubMed ID: 29453305 [TBL] [Abstract][Full Text] [Related]
13. Non-vitamin K antagonist oral anticoagulants versus vitamin K antagonists in atrial fibrillation patients with previous stroke or intracranial hemorrhage: A systematic review and meta-analysis of observational studies. Guo Z; Ding X; Ye Z; Chen W; Chen Y Clin Cardiol; 2021 Jul; 44(7):917-924. PubMed ID: 34013988 [TBL] [Abstract][Full Text] [Related]
14. Appropriateness of Non-vitamin K Antagonist Oral Anticoagulants Dosing According to Different Prescription Guides Used in Belgian Ambulatory Care. Delesie M; Ballet A; Hillegeer C; Desteghe L; Dendale P; Heidbuchel H Clin Drug Investig; 2022 Sep; 42(9):775-786. PubMed ID: 35986867 [TBL] [Abstract][Full Text] [Related]
15. Label Adherence for Non-Vitamin K Antagonist Oral Anticoagulants in a Prospective Cohort of Asian Patients with Atrial Fibrillation. Lee SR; Lee YS; Park JS; Cha MJ; Kim TH; Park J; Park JK; Lee JM; Kang KW; Shim J; Uhm JS; Kim J; Kim C; Kim JB; Park HW; Joung B; Choi EK Yonsei Med J; 2019 Mar; 60(3):277-284. PubMed ID: 30799590 [TBL] [Abstract][Full Text] [Related]
16. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies. Li G; Lip GYH; Holbrook A; Chang Y; Larsen TB; Sun X; Tang J; Mbuagbaw L; Witt DM; Crowther M; Thabane L; Levine MAH Eur J Epidemiol; 2019 Feb; 34(2):173-190. PubMed ID: 29948370 [TBL] [Abstract][Full Text] [Related]
17. Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group. Pharithi RB; Ranganathan D; O'Brien J; Egom EE; Burke C; Ryan D; McAuliffe C; Vaughan M; Coughlan T; Morrissey E; McHugh J; Moore D; Collins R Ir J Med Sci; 2019 Feb; 188(1):101-108. PubMed ID: 29860595 [TBL] [Abstract][Full Text] [Related]
18. Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis. Pan KL; Singer DE; Ovbiagele B; Wu YL; Ahmed MA; Lee M J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28720644 [TBL] [Abstract][Full Text] [Related]
19. Apixaban for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: The PAROS cross-sectional study of routine clinical practice. Falissard B; Picard F; Mahe I; Hanon O; Touzé E; Danchin N; Lamy FX; Ricci L; Steg PG Arch Cardiovasc Dis; 2019; 112(6-7):400-409. PubMed ID: 31014991 [TBL] [Abstract][Full Text] [Related]
20. Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]). Steinberg BA; Simon DN; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Kowey PR; Mahaffey KW; Peterson ED; Piccini JP; Am J Cardiol; 2017 May; 119(10):1590-1595. PubMed ID: 28363354 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]